Literature DB >> 24091941

Human TTC5, a novel tetratricopeptide repeat domain containing gene, activates p53 and inhibits AP-1 pathway.

Ying Xiong1, Lan Wang, Weiwei Deng, Junzhi Wang, Taiping Shi.   

Abstract

The transcription factor p53 and AP-1 play an important role in cellular proliferation, transformation and death. In this study, we investigated the role of a novel human gene, TTC5 (tetratricopeptide repeat domain 5), in the regulation of cell signaling pathway and cell viability. TTC5 is a member of the TTC family of proteins and has previously been shown to participate in cellular stress response. Here we demonstrate for the first time that TTC5 significantly activates p53 pathway and inhibits AP-1 transcriptional activity. Further investigation revealed that overexpression of TTC5 up-regulated p53 and p21 expression, and significantly inhibited transcriptional activity, expression and phosphorylation of c-Jun. As for the upstream of signaling pathway of AP-1, our study demonstrated that overexpression of TTC5 significantly down-regulated the expression and phosphorylation of JNK/SAPK. Moreover, overexpression of TTC5 repressed cell proliferation and induced S phase cell cycle arrest. These results indicated that TTC5 may regulate cell viability by p53 and AP-1 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24091941     DOI: 10.1007/s11033-013-2729-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  15 in total

Review 1.  Signal transduction pathways: targets for chemoprevention of skin cancer.

Authors:  A M Bode; Z Dong
Journal:  Lancet Oncol       Date:  2000-11       Impact factor: 41.316

2.  Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.

Authors:  J J Li; C Westergaard; P Ghosh; N H Colburn
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

Review 3.  AP-1 in cell proliferation and survival.

Authors:  E Shaulian; M Karin
Journal:  Oncogene       Date:  2001-04-30       Impact factor: 9.867

Review 4.  Tetratrico peptide repeat interactions: to TPR or not to TPR?

Authors:  J R Lamb; S Tugendreich; P Hieter
Journal:  Trends Biochem Sci       Date:  1995-07       Impact factor: 13.807

5.  Regulation of glucocorticoid receptor activity by a stress responsive transcriptional cofactor.

Authors:  Laura Davies; Elissavet Paraskevopoulou; Malihah Sadeq; Christiana Symeou; Constantia Pantelidou; Constantinos Demonacos; Marija Krstic-Demonacos
Journal:  Mol Endocrinol       Date:  2010-12-08

Review 6.  The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.

Authors:  Marianne Farnebo; Vladimir J N Bykov; Klas G Wiman
Journal:  Biochem Biophys Res Commun       Date:  2010-05-21       Impact factor: 3.575

7.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

8.  INMAP, a novel truncated version of POLR3B, represses AP-1 and p53 transcriptional activity.

Authors:  Zhou Yunlei; Chen Zhe; Lei Yan; Wang Pengcheng; Zheng Yanbo; Sun Le; Liang Qianjin
Journal:  Mol Cell Biochem       Date:  2012-11-04       Impact factor: 3.396

Review 9.  The P53 pathway: what questions remain to be explored?

Authors:  A J Levine; W Hu; Z Feng
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

10.  A TPR motif cofactor contributes to p300 activity in the p53 response.

Authors:  C Demonacos; M Krstic-Demonacos; N B La Thangue
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

View more
  3 in total

1.  The Effect of Wenxin Keli on the mRNA Expression Profile of Rabbits with Myocardial Infarction.

Authors:  Min Zheng; Zhouying Liu; Nana Liu; Cuihong Hou; Jielin Pu; Shu Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-24       Impact factor: 2.629

2.  TTC5 syndrome: Clinical and molecular spectrum of a severe and recognizable condition.

Authors:  Luciana Musante; Flavio Faletra; Kolja Meier; Hoda Tomoum; Paria Najarzadeh Torbati; Edward Blair; Sally North; Jutta Gärtner; Susann Diegmann; Mehran Beiraghi Toosi; Farah Ashrafzadeh; Ehsan Ghayoor Karimiani; David Murphy; Flora Maria Murru; Caterina Zanus; Andrea Magnolato; Martina La Bianca; Agnese Feresin; Giorgia Girotto; Paolo Gasparini; Paola Costa; Marco Carrozzi
Journal:  Am J Med Genet A       Date:  2022-06-07       Impact factor: 2.578

3.  Evaluation of the Role of p53 Tumour Suppressor Posttranslational Modifications and TTC5 Cofactor in Lung Cancer.

Authors:  Hasen Alhebshi; Kun Tian; Lipsita Patnaik; Rebecca Taylor; Pavel Bezecny; Callum Hall; Patricia Anthonia Johanna Muller; Nazila Safari; Delta Patricia Menendez Creamer; Constantinos Demonacos; Luciano Mutti; Mohamad Nidal Bittar; Marija Krstic-Demonacos
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.